Exelixis(NASDAQ:EXEL) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 3, 2016. Company reported revenue of $36.25M. Analysts estimated a revenue of $17.96M. Earnings per share were $-0.16. Analysts had estimated an EPS of $-0.27.
Exelixis (EXEL) remained unchanged at the close of Friday session. Even as the volume increased to 25,05,582 ,the shares failed to make any impression and ended at 0 points or 0.00% at $10.66. The trading session commenced at $10.62 and the stock hit a high of $10.715 and touched $10.54 at the lower end. Considering that the stock pared all of the losses, it can be said as a positive sign. The share price has a 52-week high of $11.66 and the 52-week low is $3.55. The company has a market cap of $2,455 M and has approximately 23,03,25,740 outstanding shares.
Several Insider Transactions has been reported to the SEC. On May 11, 2016, Lance Willsey (director) purchased 60,000 shares at $4.96 per share price.Also, On Oct 19, 2015, Peter Lamb (EVP, Discovery Research & CSO) sold 51,549 shares at $5.80 per share price.
Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive metastatic medullary thyroid cancer (MTC) in the United States. The Company’s other programs include metastatic renal cell carcinoma (mRCC) a phase III trial comparing cabozantinib to everolimus in patients with mRCC who have experienced disease progression following treatment with at least one prior VEGFR TKI; CELESTIAL a phase III trial comparing cabozantinib with placebo in patients with advanced hepatocellular cancer (HCC) who have previously been treated with sorafenib; NSCLC (non-small cell lung cancer); mCRPC (metastatic castration-resistant prostate cancer) and XL888 a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90).